Shots:Remegen has reported P-III trial data assessing telitacicept vs PBO in pts with primary Sjögren's syndromeTrial met its 1EP of reduced EULAR Sjögren’s syndrome disease activity index (ESSDAI), showing improved disease activity at Wk. 24; NMPA’s BLA submission is planned, along with presentation of detailed data at an upcoming conferenceTelitacicept is a…